Efficacy of Spironolactone Therapy in Patients With True Resistant Hypertension
Efficacy of Spironolactone Therapy in Patients With True Resistant Hypertension
复制标题
DOI：
10.1161/hypertensionaha.109.140988
复制
发表时间：
2010-01-01
期刊：
影响因子：
8.3
通讯作者：
Salles, Gil
中科院分区：
文献类型：
--
作者：
de Souza, Fabio;Muxfeldt, Elizabeth;Salles, Gil
螺内酯在顽固性高血压治疗中的作用尚不清楚。这项前瞻性试验的目的是评估螺内酯对通过动态血压监测诊断的真正难治性高血压患者的降压效果。共有175名患者在基线时进行了临床检查和补充检查，并接受了剂量为25至100mg /d的螺内酯治疗。在平均间隔7个月后进行第二次动态血压监测。使用配对学生t检验来评估服用螺内酯前和服用期间的血压差异，并通过调整年龄、性别和降压药数量的多变量分析来评估血压下降的预测因素。24小时收缩压和舒张压分别平均降低16和9毫米汞柱(95% ci: 13 ~ 18和7 ~ 10毫米汞柱
The role of spironolactone in resistant hypertension management is unclear. The aim of this prospective trial was to evaluate the antihypertensive effect of spironolactone in patients with true resistant hypertension diagnosed by ambulatory blood pressure monitoring. A total of 175 patients had clinical and complementary exams obtained at baseline and received spironolactone in doses of 25 to 100 mg/d. A second ambulatory blood pressure monitoring was performed after a median interval of 7 months. Paired Student t test was used to assess differences in blood pressure before and during spironolactone administration, and multivariate analysis adjusted for age, sex, and number of antihypertensive drugs to assess the predictors of blood pressure fall. There were mean reductions of 16 and 9 mm Hg, respectively, in 24-hour systolic and diastolic blood pressures (95% CIs: 13 to 18 and 7 to 10 mm Hg; P